The effects on bone marrow (BM) cell proliferation and differentiation of recombinant human interleukin-3 (rhlL-3) and recombinant human granulocyte-macrophage colonystimulating factor (rhGM-CSF) administered after high-dose (7 g/m2/d) cyclophosphamide (HD-CTX) chemotherapy were studied in nine patients with malignancies without BM involvement and in three control patients. rhlL-3 at a dose of 1 t o 5 pglkglday was administered for 14 t o 18 days by continuous intravenous (IV) infusion and rhGM-CSF was administered at a dose of 5.5 pglkglday for 14 days. Changes induced by cytokine treatment were assessed by morphoimmunohistochemical analysis of BM biopsies. Comparison was made in the cytokine-treated groups and with control patients who received HD-CTX alone. BM cellularity and the myeloidlerythroid (ME) ratio were lower in rhlL-3-treated than in rhGM-CSF-treated patients, but in both groups it was significantly higher than in the controls. The proportion of BM cells stained by PC10, a monoclonal ROLIFERATION and differentiation of hematopoi-P etic progenitor cells require the presence of specific growth factors known as CSF.' Among them, interleukin-3 (IL-3) and GM-CSF are effective in supporting proliferation of multipotent progenitors and both show a wide target spectrum, including cells of the myeloid, megakaryocytic, and early erythroid lineages.2
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regarding the in vivo activity of rhIL-3.7-11 According to recent reports, IL-3 administered to subjects with normal hematopoiesis or patients with BM failure induces a multilineage response, with an increase in neutrophil, eosinophil, monocyte, reticulocyte, and platelet numbers in the peripheral blood (PB). 8 In the bone marrow (BM), rhIL-3 increases the cellularity, causes a shift to the left and marked eosinophilia.8J0 Progenitor cell assays show an rhIL-3-induced increase in cycling status of CFU-GM, CFU-GEMM, and BFU-E in patients with normal hematopoietic function. No increase in the cycling rate of BM progenitors is noted in patients with BM failures from prolonged chemotherapy,8 aplastic anemia,9 and myelodysplastic syndrome^.^ Preliminary evidence shows that differences exist in the time of onset and extent of leukocytosis induced by rhIL-3 as compared with rhGM-CSF.'O We wished to document the effects of rhIL-3 administered to six patients with breast carcinoma after a course of cyclophosphamide cancer chemotherapy. A comparison was made with three patients with Hodgkm's (HD) and non-Hodglun's lymphomas (NHL) who received the same HD-CTX treatment followed by rhGM-CSF infusion and with a group of three other patients with HD who were treated by HD-CTX alone. To this end, we analyzed the changes in proliferation of early and late precursors and their progeny on BM biopsies. We also studied the stromal modifications in the BM of the same patients. protocols6J2 approved by our institute's ethical committee for first-line treatment of malignancies with poor prognosis. Beginning 24 hours after cyclophosphamide 7 g/m2 (HD-CTX, day 0), three groups of two patients with breast cancer received rhIL-3 (Sandoz, Basel, Switzerland) at 1.0, 2.5, and 5 pgikg body weight by continuous daily intravenous (IV) infusion. This study was part of a dose-finding study. The treatment continued from day +1 to day +14 to 18 ( Table 1) .
IN VIVO EFFECT OF CYTOKINES ON HUMAN BM
The three patients with high-grade NHL (patients 7 and 8), and HD (patient 9) received rhGM-CSF (Sandoz) 5.5 pg/kg from day + 1 to day + 10 to 16 (Table l) , starting 24 hours after HD-CTX.
BM trephine biopsy was taken shortly before the HD-CTX administration and after hematopoietic recovery from chemotherapy-induced pancytopenia, between 16 and 20 days after HD-CTX treatment, and between 1 and 6 days after cytokine discontinuation ( Table 1) .
The control group included three patients treated with HD-CTX with no subsequent cytokine treatment with an available BM biopsy taken at a time interval comparable to that of the cytokinetreated patients. None of the rhIL-3-treated breast cancer patients had previously received chemotherapy and/or radiotherapy. The two rhGM-CSF-treated NHL cases had previously received MACOP-B13 chemotherapy which had ended more than 8 months before the start of HD-CTX treatment, at which time their hematopoiesis was fully recovered. All HD patients (rhGM-CSFtreated patient 9 plus the three controls) had previously been treated with MOPP/ABVDL4 chemotherapy. The mean interval between the last course of this latter treatment and start of the HD-CTX treatment was 7.5 months (range 6.5 to 8 months). When this treatment was started, their hematopoiesis was normal. No NHL or HD patient had received radiation therapy. The main characteristics of these patients are shown in Table 1 .
All PB samples drawn in EDTA were analyzed with an automated Technicon H6000 blood counter. Pretreatment blood samples were collected within 1 day before HD-CTX administration. Posttreatment samples were drawn at day +20 after HD-CTX administration, on the same day of posttreatment BM biopsy in most patients (Table 1) . For response evaluation, the results from cytokine-treated patients were compared with the controls.
BM trephine biopsies were fixed in 10% buffered formalin for 4 hours and then decalcified in 10% Titriplex (Merck, PB analysis.
BM biopsy.
Darmstadt, Germany) and embedded in paraffin; 5-hm-thick sections were dried on polylysine-treated glass slides at 37°C overnight, deparaffinized by serial passages in xylene and in a graded alcohol series, and rehydrated in distilled water. Hematoxylin and eosin, toluidine blue, and Gomori's reticulin silver stain were used routinely on all samples.
Immunohistochemical methods. Single-stain immunohistochemistry was performed as previously described? deparaffinized slides were covered with AB human serum for 15 minutes, blotted, and then incubated overnight at 4°C with the primary antibodies and with the negative control serum ( Double staining17 for proliferating cell nuclear antigens (PCNA) and antigens that do not require trypsinization were performed by staining first the membrane or cytoplasmic antigen with a biotinconjugated horse anti-mouse antibody (1:200, Vector; 45 minutes), followed by an avidin biotin-peroxydase complex (ABC Elite, Vector; 30 minutes) and developing with aminoethyl carbazole (AEC; Sigma). The slides were then incubated overnight with the PClO antibody, washed, and counterstained with a biotinconjugated horse anti-mouse antibody as above. Finally, alkaline phosphatase-conjugated streptavidin was added and the reaction was demonstrated in blue with fast blue BB diazonium salt (Sigma) and naphtol AS BI ph0~phate.l~ Because PClO epitope does not survive enzymatic treatment, it was stained first by immunoperoxidase with AEC as a developer, followed by trypsinization and then by immunostaining in blue for and then by PClO red staining in AF'AAP. Immunohistochemical reactivity was expressed as a percentage of stained cells on the total number of BM nucleated cells as previously described.m Cells were counted at ~1,000 with a 10 x 10-mm ocular grid on areas measuring at least 10 mm2, excluding cortical and trabecular bone, fat, periosteal connective tissue, and areas of hemorrhage. The reticulin content of the BM was graded according to the scoring system proposed by Manoharan et alF1
Identification of BM hematopoietic cell lines and differentiation and stromal cellpopulations. Antibody QBEndlO is a CD34 antibody" that stains formalin-fixed, paraffin-embedded material23 and identifies in the BM a small population of immature lymphoidappearing cells, with colony-forming ability in vitro." It also stains endothelial cells (described below).
LN3 recognizes HLA-Dr on routine paraffin-embedded specimens.25 The HLA-Dr+ cells contain most of the CD34+ progenitors, myeloblasts, and mono blast^,^,^^ whereas more mature myeloid elements (neutrophilic, erythroid, megakaryocytic) are nega t i~e . 2~
Chloroacetate esterase (CAE) is a cytoplasmic enzyme contained in the primary granules of the granulopoietic cells, greatly expressed at the level of promyelocytes and then in their p r~g e n y . '~ Double staining of the normal BM for HLA-Dr and CAE demonstrated very few double-stained cells (G. Cattoretti, unpublished observations, January 1991), consistently with reduced HLA-Dr expression at the promyelocyte CAE staining allows identification of eosinophilic granulopoietic differentiation as well
The monocytic/macrophagic series was identified by CD68 staining28; the KiM6 antibody, differently from other CD68 antibodi e~,~~ is restricted to the monocyte/macrophage series and does not stain granulopoietic cells, megakaryocytes, vessels, and epithelia.30 It works on formalin-fixed, paraffin-embedded specimens with the same specificity and reactivity as in frozen materiaL3' Basophils and mast cells were stained with toluidine blue.I9 The erythroid and megakaryocytic elements were identified by glycophorin A32 and platelet GPIII"(CD61)33 staining, respectively.
The BM stroma is composed of fibroblastic reticular cells,34 adipocytes, endothelial cells, and macrophages (described above). The BM fibroblasts were identified selectively by ME20.4 staining. This antibody, which recognizes the nerve growth factor receptor (NGF-R),35 stains several cell types of neuroectodermic, mesodermic, and endodermic origin, and a subset of periadventitial and perineural fibroblast^.^^ NGF-R+ BM cells were observed in a separate investigation (G. Cattoretti et al, manuscript in preparation, December 1991) to be positive for alkaline phosphatase, Vimentin, CD13 antigen, collagen III", and reticulin, and negative for a variety of leukocyte (CD45, CD68), endothelial (von Willebrand factor, Pal-E, EN4, CD34, CD36, collagen IV"), and adipocyte (S-100, CD36, collagen IV") markers. No BM elements other than reticular cells were stained by the ME20.4 MoAb.
The BM endothelium, identified by CD34 stainingU or by combined reticulin and CD34 staining (not shown), was expressed as the percentage of positive endothelial cells on the total number of BM nucleated cells.
PClO is an MoAb reactive with a DNA polymerase-&accessory (CAI-).
protein, the so-called PCNA, associated with cell p r~l i f e r a t i o n~~ and normally expressed in the BM only by cells of myelocyte or earlier m~rphology?~ Assessment of the proliferative fraction in each cell lineage by double immunohistochemistry was feasible for the BM lineages and differentiation step, for which a suitable antibody (ie, a reagent of defined specificity, reacting with formalinfixed tissue) was available. Some cell types could not be identified with a positive staining, either because of the lack of a specific marker (eg, eosinophils) or because of a dim antigenic expression (eg, proerythroblasts). This resulted in a fraction of proliferating PClO+ cells that could not be allocated to a given lineage. Evaluation of the data was performed by standard statistical methods provided by an IBM-compatible statistical analysis package program (StatPac; Walonick Associates, Minneapolis, MN). Student's t-test for paired data was used to make comparisons between pretreatment and posttreatment results of both cytokine-treated groups. In addition, Student's t-test for independent groups and variance analysis was used to compare posttreatment results of the rhIL-3 and rhGM-CSF groups and the controls.
Statistical analysis.
RESULTS
rhIL-3-treated patients showed significantly higher WBC (P < .03), neutrophil (P < .02), and platelet (P < .005) counts at day +20 after HD-CTX therapy as compared with controls (Table  3 ). In addition, in rhGM-CSF-treated patients, the WBC (P < .003) and neutrophil (P < .002) counts were significantly higher than those of the controls at day +20 after HD-CTX administration. Platelet counts also increased after treatment with rhGM-CSF, although such increase, owing to the small number of cases examined, was not significant. Monocyte, eosinophil, basophil counts, and hemoglobin level were not significantly changed after cytokine treatment in either groups. Treatment with rhGM-CSF as compared with rhIL-3 resulted in higher WBC (P < .002) and neutrophil counts (P < .001). The results observed in our small control group were similar to the data previously reported in a larger group of patients with comparable clinical characteristics treated with HD-CTX alone. 6 The three groups studied showed comparable pretreatment BM parameters (P = NS, not shown). The effects on BM of HD-CTX alone v HD-CTX plus cytokines were assessed by comparing the three groups. The increased cellularity (P < .04), myeloid/ erythroid (ME) ratio (P = .001), PClO (P < .04), CD61 (P < .Ol), HLA-Dr (P < .005), endothelial cells (P < .005), and proliferating myeloid cells (Dr/PC10, P < .03; CAE/ PC10, P = .01) and the decreased erythroid BM component (P < .01) observed only in cytokine-treated patients showed that these changes resulted from the latter hormones and not the cytoxan treatment ( Table 4 ). The posttreatment values of myeloblasts, basophils, and mast cells were within normal ranges and virtually unchanged with respect to the pretreatment figures.
In addition, marrow cellularity before (Fig 1A through C ) and after (Fig 1B through D) cytokine treatment was compared in rhIL-3 and rhGM-CSF patients: Only rhGM-CSF patients had a significantly increased posttreatment PB changes and effects of treatment.
BM changes induced by treatment.
For 
1.30
PB cell count and WBC differential was assessed before (pre) and after (+20 days post) HD-CTX and cytokine or HD-CTX alone (controls) treatment. All counts are 109/L; hemoglobin is given as gldL.
Abbreviations: Neut, neutrophils; Mono, monocytes; Eos, eosinophils; Bas, basophils; Lymph, lymphocytes; Plt, platelets; Hb, hemoglobin. 
Erv ( BM cellularity and ME ratio: before (A) and after (B) CTX-rhlL-3 treatment (patient 3) (original magnification ~200); before (C) and after ( 0 ) CTX-rhGM-CSF treatment (patient 9) (original magnification x 130). value (P < .02) (Fig ID) . Both groups showed posttreatment left-shifted myeloid hyperplasia (Table 4) , with a significantly increased ME ratio (rhlL-3, P < .05; rhGM-CSF, P < .04). No patient had significant distortion in BM topography. In patients with increased ME ratio, promyelocytes and myelocytes formed thick rims at the endosteal surface of the trabeculae or large periarteriolar clusters (Fig 2) . Significant differences between pretreatment and posttreatment values were observed for promyelocytes (rhIL3,P < .01; rhGM-CSF,P = .05),eosinophils(rhlL-3, P < .03), erythroid precursors (rhIL-3, P = .05), and megakaryocytcs. These latter evaluated by CD61, were significantly different between the groups ( P < .01). The other changes observed were not statistically significant. Erythroid precursors and megakaryocytes were normally distributed in the intertrabecular areas. In one patient (patient 5 ) several hyperplastic lymphoid follicles were observed in the BM biopsy performed after IL-3 administration.
The frequency of CD34+ BM cells was unchanged after treatment in rhlL-3 and control patients but was decreased in all rhGM-CSF patients from 0.90% & 0.16 to 0.27% 5 0.12 (P < .001) ( Table 5 ). CD34+ cells appeared as single small randomly scattered cells (Fig 3A) . Some larger cells were observed occasionally. .-
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HLA-Dr expression on progenitors and early precursors increased in the rhGM-CSF group (P = .01) but not in the other two groups. Low HLA-Dr expression correlated with the low frequency of morphologically identifiable myeloblasts, and was observed in myelopoietic areas in single cells, surrounded by more mature myeloid cells (promyelocytes, myelocytes, and metamyelocytes). A minimal fraction of BM B-lymphoid cells, identified by CD45Ra staining (not shown), was contained in the HLA-Dr+ population.
BM expression of the PCNA (PC10) was significantly increased after both rhIL-3 and rhGM-CSF treatment ( Fig   3B) but not in the controls (rhIL-3, P < .02; rhGM-CSF, P < .001; controls, P = NS). Some variation in the percentage of PClO positivity after cytokine treatment could be related to the different time points for BM examination, which varied from 1 to 6 days after discontinuation of the growth factor. Our results show, however, that PClO expression in later samples (days +3 to 6) was not significantly lower than that in earlier samples (days +1 to 2)
(P = NS).
The results discussed above were reanalyzed taking into account the change in cellularity induced by treatment, ie, adjusting each determined value to an arbitrary cellularity of 100%. This correction did not alter the significance of the results (data not shown).
Double-immunohistochemical analysis allowed us to assign PC10+ cells to the different hematopoietic lineages. Most of the PC10+ cells coexpressed CAE, and a few were HLA-Dr+ (rh-IL3, 3%; rhGM-CSF, 8%). Of the former, most showed promyelocyte characteristics (presence of nucleoli, intense CAE staining), and a few resembled neutrophilic myelocytes (absence of nucleoli, weak CAE staining). Positive PClO/CAE staining made clusters of granulocyte precursors easy to recognize (Fig 2) .
The remaining PC10+ myeloid cells consisted mostly of eosinophilic myelocytes, corresponding to morphologically identifiable PClO+/CAE-myelocytes (Fig 2) . With the exception of two rhIL-3 patients (patients 3 and 5) in which increased PClO expression after treatment was observed on clusters of glycophorin+ erythroid precursors (Fig 3C and  D) , in the remaining patients only a small proportion of the PClO reactivity resulted from these cells or from megakaryocytes (not shown). The treatment protocols (cytokines v controls) did not result in a significant difference in the fraction of CD34+/PC10+ (P = NS), whereas the differences in HLA-Dr+/PC10+ and CAE+/PClO+ between the three groups were statistically significant (P = .03 and P = .01, respectively) (Fig 4) .
BM: Morphoimmunophenotypic ana&sis of the hematopoietic microenviroment. After cytokine treatment, the BM vascular network was much increased and showed branching, tortuosity, and dilatation. The proportion of endothelial cells of BM arterioles, capillaries, and sinusoids expressing CD34 was also significantly increased (Table 5) in the cytokine groups v the controls (P = .004). Patient 9 had had increased CD34 endothelial reactivity before treatment. Sinusoidal dilatation observed in most patients in the control group was not associated with increased CD34 expression.
For personal use only. on November 15, 2017. by guest www.bloodjournal.org From ORAZl ET AL a Reticulin (Fig 5A and B) and collagen 111" (not shown) was increased in five of six rhIL-3 patients (Table 5) , whereas no increase was observed in the rhGM-CSF or the control group. The increased BM reticulin content consisted of a fine diffuse network with focal increase in coarse fibers (Fig 5A and B) . Double-labeling with CD34 (not shown) showed that most reticulin fibers belonged to the much increased vascular network observed in these BM. Some focal increase in reticulin content was also observed in megakaryocyte-rich areas. In both groups, an increase in the number of NGF-R+ fibroblasts was observed after treatment (Fig 5C and D) .
Increased numbers of morphologically identifiable CD68+ BM macrophages were observed after treatment (Fig 5E  and F) (Table 5) Results are mean f SD from six IL-3, three GM-CSF, and three control patients. P values were obtained by Student's t test. showed a few multivacuolated lypocytes in the posttreatment sample; muscle actin expression on myofibroblasts was undetectable in all patients.
DISCUSSION
We focused on the BM effects of combined HD-CTX and rhIL-3 or rhGM-CSF treatment to the BM, examined in situ on biopsies. This approach avoids dilution of BM aspirates with PB, particularly relevant in the presence of BM fibrosis,3x and allows assessment of spatial distribution of the various hematopoietic cell populations, including very rare cells like the CD34+ progenitors. Finally, we were able to study the changes induced on BM stroma by the treatment.
The double-immunostaining technique we used, in which a lineage-specific marker is coupled with the PCNA staining, allowed us to estimate the proliferative status of single cells with no further manipulation of the BM material. We exploited PCNA expression, which occurs in cycling cells from late GI to early GI phase,3y as a novel means for cytokinetic analysis of BM cells exposed in vivo to HD-CTX and growth factors. Using this method, we were able to compare changes in the absolute number of proliferating cells and document a differential effect for the two cytokines on different lineages; ie, preferential stimulation of erythroid cells after rhIL-3 infusion and of HLA-Dr+ cells in rhGM-CSF-treated subjects.
Comparative effect of rhIL-3 and rhGM-CSF on BM cellularity and on hematopoietic lineages. In the rhIL-3 group, the absolute BM cellularity was unchanged and the ME ratio was not increased to the high levels of the rhGM-CSF patients. This latter difference resulted largely For personal use only. on November 15, 2017. by guest www.bloodjournal.org From from the lack of response observed in patient 2. In all patients, the cytokines appeared more efficient at inducing active cycling of the amplification compartment, including erythroid and megakavocytic lines, than at increasing the number of immature precursors. A similar effect in a murine system was described previously.w42 Most BM proliferating cells were shown to belong to the morphologically recognizable differentiation steps of the myeloid lineages, in which promyelocytes and myelocytes make most of the PCNA+ cells. In both groups, immature eosinophils also proliferate, a finding not yet reported by other investigators. The absence of an IL-3 receptor on mast cells43 may account for the unchanged concentration of these cells after rhIL-3 treatment.
Several reports have evaluated progenitor cells under cytokine treatment: the number of functionally assessed precursors (ie, CFU-GM, BFU-E, CFU-GEMM, CFU-S) has been shown to remain steady or to be decreased (because of dilution effect) when a low or intermediate dose of IL-3 and GM-CSF is administeredw; a high dose of IL-3 can increase the absolute number of progenitors in a Effect on myelopoiesis dissected by phenotypic study. murine system!' Conversely, GM-CSF or IL-3 increases the cycling rate of progenitor cells. lO.u In humans, some of the functional assays for stem cells (ie, CFU-S) are not feasible and quantitating the number of progenitor cells per organ (BM or spleen) is not possible." We used the QBEndlO CD34 antibody to evaluate the frequency of the progenitor-containing cell population in our material. We failed to detect either a numerical increase or a focal accumulation or increased proliferation rate of CD34+ cells. Besides a dilutional effect caused by overgrowth of mature end cells,'" this may result from cytokine-induced mobilization of CD34+ cells and consequent redistribution outside the BM compartment.t2*26 Our morphologic and immunophenotypic analysis also confirms that the combined HD-CTX and cytokine treatment spares the BM pool of CD34+ cells and that their distribution, frequency, and proliferative status are maintained.
Stromal changes observed after treatment included an increase in the number of BM NGF-R+ fibroblasts observed in both groups but not in the controls and may have been a direct effect of the treatment received. A stimulatory effect on BM fibroblast CFU-F was Effect on BM stroma.
For personal use only. on November 15, 2017. by guest www.bloodjournal.org From 2618 ORA21 ET AL recently described for GM-CSF,45 but similar data have not been reported for IL-3 or other endogenously produced cytokines. Increases in reticulin and collagen I11 deposition observed in rh-11-3-treated cases and not observed in our rhGM-CSF-treated patients may be mediated by accessory cells or megakaryocyte-derived fibroblast-stimulating factors such as PDGF and TGFp. 46 Our data show that in BM stimulated by both rhIL-3 and rhGM-CSF CD34+ sinusoidal cells were significantly increased with respect to controls. These findings are in agreement with those of recent studies47 showing that G-CSF and GM-CSF can influence migration and proliferation of human endothelial cells in culture. Several experimental data show that the functional integrity of the sinus wall prevents immature cells from gaining access to the circulation.@ Proliferation of endothelial cells and increased sinusoidal tortuosity was described in the BM of rats and mice with acute myeloid leukemia and was believed to be responsible for the entry of myeloblasts in the circulation.@ Similarly, in cytokine-treated BM, sinus wall alterations could facilitate egression of progenitors and immature precursors and contribute to the process of redistribution to the PB of these cells. We conclude that a combined morphologic and immunohistochemical approach allowed us to evaluate the overall BM effects of cytokine treatment accurately and to obtain information unavailable by other approaches.
